On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer

Literature Cited

1. Alexandre YO, Ghilas S, Sanchez C, Le Bon A, Crozat K, Dalod M 2016. XCR1⁺ dendritic cells promote memory CD8⁺ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses. J. Exp. Med. 213:175–92
   [Google Scholar]
2. Allen BM, Hiam KJ, Burnett CE, Venida A, DeBarge R et al. 2020. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat. Med. 26:71125–34
   [Google Scholar]
3. Alraies Z, Rivera CA, Delgado M-G, Sanséau D, Maurin M et al. 2022. An Arp2/3-cPLA₂-NFκB axis acts as a cell shape sensor to drive homeostatic migration of dendritic cells. bioRxiv . https://doi.org/10.1101/2022.08.09.503223
   [Crossref]
4. Alshetaiwi H, Pervolarakis N, McIntyre LL, Ma D, Nguyen Q et al. 2020. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol 5:44aay6017
   [Google Scholar]
5. Ardouin L, Luche H, Chelbi R, Carpentier S, Shawket A et al. 2016. Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery. Immunity 45:2305–18
   [Google Scholar]
6. Asrir A, Tardiveau C, Coudert J, Laffont R, Blanchard L et al. 2022. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell 40:3318–34.e9
   [Google Scholar]
7. Baer JM, Zuo C, Kang L-I, de la Lastra AA, Borcherding NC et al. 2022. Pancreas resident macrophage-induced fibrosis has divergent roles in pancreas inflammatory injury and PDAC. bioRxiv . https://doi.org/10.1101/2022.02.09.479745
   [Crossref]
8. Baratin M, Foray C, Demaria O, Habbeddine M, Pollet E et al. 2015. Homeostatic NF-κB signaling in steady-state migratory dendritic cells regulates immune homeostasis and tolerance. Immunity 42:4627–39
   [Google Scholar]
9. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD et al. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21:6822–35
   [Google Scholar]
10. Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, Álvarez R, Mato-Berciano A et al. 2021. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J. Immunother. Cancer 9:11e003254
    [Google Scholar]
11. Becht E, Tolstrup D, Dutertre C-A, Morawski PA, Campbell DJ et al. 2021. High-throughput single-cell quantification of hundreds of proteins using conventional flow cytometry and machine learning. Sci. Adv. 7:39eabg0505
    [Google Scholar]
12. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature 393:6684478–80
    [Google Scholar]
13. Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA et al. 2019. Unleashing type-2 dendritic cells to drive protective antitumor CD4⁺ T cell immunity. Cell 177:3556–71.e16
    [Google Scholar]
14. Binnewies M, Pollack JL, Rudolph J, Dash S, Abushawish M et al. 2021. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell Rep 37:3109844
    [Google Scholar]
15. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF et al. 2018. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24:5541–50
    [Google Scholar]
16. Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S et al. 2020. Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Rep 30:2481–96.e6
    [Google Scholar]
17. Boettcher S, Manz MG. 2017. Regulation of inflammation- and infection-driven hematopoiesis. Trends Immunol 38:5345–57
    [Google Scholar]
18. Böttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M et al. 2018. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172:51022–37.e14
    [Google Scholar]
19. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL et al. 2014. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26:5638–52
    [Google Scholar]
20. Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V et al. 2017. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130:6753–62
    [Google Scholar]
21. Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. 2021. Dendritic cells revisited. Annu. Rev. Immunol. 39:131–66
    [Google Scholar]
22. Campesato LF, Budhu S, Tchaicha J, Weng C-H, Gigoux M et al. 2020. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 11:4011
    [Google Scholar]
23. Cancel J-C, Crozat K, Dalod M, Mattiuz R. 2019. Are conventional type 1 dendritic cells critical for protective antitumor immunity and how?. Front. Immunol. 10:9
    [Google Scholar]
24. Canton J, Blees H, Henry CM, Buck MD, Schulz O et al. 2021. The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat. Immunol. 22:2140–53
    [Google Scholar]
25. Caronni N, Piperno GM, Simoncello F, Romano O, Vodret S et al. 2021. TIM4 expression by dendritic cells mediates uptake of tumor-associated antigens and antitumor responses. Nat. Commun. 12:2237
    [Google Scholar]
26. Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J et al. 2021. Tissue-resident macrophages provide a protumorigenic niche to early NSCLC cells. Nature 595:7868578–84
    [Google Scholar]
27. Casey SC, Tong L, Li Y, Do R, Walz S et al. 2016. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352:6282227–31
    [Google Scholar]
28. Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM et al. 2019. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 35:4588–602.e10
    [Google Scholar]
29. Cheng S, Li Z, Gao R, Xing B, Gao Y et al. 2021. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184:3792–809.e23
    [Google Scholar]
30. Cohen M, Giladi A, Barboy O, Hamon P, Li B et al. 2022. The interaction of CD4⁺ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nat. Cancer 3:3303–17
    [Google Scholar]
31. Colbeck EJ, Ager A, Gallimore A, Jones GW. 2017. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?. Front. Immunol. 8:1830
    [Google Scholar]
32. Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI et al. 2018. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9:771
    [Google Scholar]
33. Coombs CC, Zehir A, Devlin SM, Kishtagari A, Syed A et al. 2017. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21:3374–82.e4
    [Google Scholar]
34. Dähling S, Mansilla AM, Knöpper K, Grafen A, Utzschneider DT et al. 2022. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. Immunity 55:4656–70.e8
    [Google Scholar]
35. Danenberg E, Bardwell H, Zanotelli VRT, Provenzano E, Chin S-F et al. 2022. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat. Genet. 54:5660–69
    [Google Scholar]
36. DeNardo DG, Ruffell B. 2019. Macrophages as regulators of tumor immunity and immunotherapy. Nat. Rev. Immunol. 19:6369–82
    [Google Scholar]
37. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315:5808107–11
    [Google Scholar]
38. Duong E, Fessenden TB, Lutz E, Dinter T, Yim L et al. 2022. Type I interferon activates MHC class I-dressed CD11b⁺ conventional dendritic cells to promote protective antitumor CD8⁺ T cell immunity. Immunity 55:2308–23.e9
    [Google Scholar]
39. Dutertre C-A, Becht E, Irac SE, Khalilnezhad A, Narang V et al. 2019. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity 51:3573–89.e8
    [Google Scholar]
40. Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K et al. 2015. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell 162:61322–37
    [Google Scholar]
41. Enamorado M, Iborra S, Priego E, Cueto FJ, Quintana JA et al. 2017. Enhanced antitumor immunity requires the interplay between resident and circulating memory CD8⁺ T cells. Nat. Commun. 8:16073
    [Google Scholar]
42. Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F et al. 2021. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut 70:71345–61
    [Google Scholar]
43. Ferris ST, Durai V, Wu R, Theisen DJ, Ward JP et al. 2020. cDC1 prime and are licensed by CD4⁺ T cells to induce antitumor immunity. Nature 584:7822624–29
    [Google Scholar]
44. Francica B, Burdette D, Clark R, Cope J, Freund D et al. 2022. Systemic small molecule TREX1 inhibitors to selectively activate STING in the TME of metastatic disease. Cancer Res 82:12 Suppl.2075 (Abstr.)
    [Google Scholar]
45. Fu T, Dai L-J, Wu S-Y, Xiao Y, Ma D et al. 2021. Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. J. Hematol. Oncol. 14:98
    [Google Scholar]
46. Fu X-T, Dai Z, Song K, Zhang Z-J, Zhou Z-J et al. 2015. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int. J. Oncol. 46:2587–96
    [Google Scholar]
47. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:57951960–64
    [Google Scholar]
48. Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S et al. 2018. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49:61148–61.e7
    [Google Scholar]
49. Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J et al. 2009. A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer. Am. J. Clin. Oncol. 32:3269–73
    [Google Scholar]
50. Gerhard GM, Bill R, Messemaker M, Klein AM, Pittet MJ. 2021. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J. Exp. Med. 218:1e20200264
    [Google Scholar]
51. Germain C, Gnjatic S, Dieu-Nosjean M-C. 2015. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front. Immunol. 6:67
    [Google Scholar]
52. GeurtsvanKessel CH, Willart MAM, Bergen IM, van Rijt LS, Muskens F et al. 2009. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206:112339–49
    [Google Scholar]
53. Ghislat G, Cheema AS, Baudoin E, Verthuy C, Ballester PJ et al. 2021. NF-κB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci. Immunol. 6:61eabg3570
    [Google Scholar]
54. Giles AJ, Reid CM, Evans JD, Murgai M, Vicioso Y et al. 2016. Activation of hematopoietic stem/progenitor cells promotes immunosuppression within the pre-metastatic niche. Cancer Res 76:61335–47
    [Google Scholar]
55. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S et al. 2009. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69:52000–9
    [Google Scholar]
56. Goc J, Germain C, Vo-Bourgais TKD, Lupo A, Klein C et al. 2014. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8⁺ T cells. Cancer Res 74:3705–15
    [Google Scholar]
57. Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M et al. 2019. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann. Oncol. 30:81381–92
    [Google Scholar]
58. Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ et al. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159:61327–40
    [Google Scholar]
59. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N et al. 2014. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14:8571–78
    [Google Scholar]
60. Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A et al. 2019. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Sci. Immunol. 4:42aax8189
    [Google Scholar]
61. Hammerich L, Marron TU, Upadhyay R, Svensson-Arvelund J, Dhainaut M et al. 2019. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 25:5814–24
    [Google Scholar]
62. Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. 2006. Tumor progression despite massive influx of activated CD8⁺ T cells in a patient with malignant melanoma ascites. Cancer Immunol. Immunother. 55:101185–97
    [Google Scholar]
63. Hegde S, Krisnawan VE, Herzog BH, Zuo C, Breden MA et al. 2020. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37:3289–307.e9
    [Google Scholar]
64. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H et al. 2008. Batf3 deficiency reveals a critical role for CD8α⁺ dendritic cells in cytotoxic T cell immunity. Science 322:59041097–100
    [Google Scholar]
65. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP et al. 2018. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 36:4359–66
    [Google Scholar]
66. Hor JL, Whitney PG, Zaid A, Brooks AG, Heath WR, Mueller SN. 2015. Spatiotemporally distinct interactions with dendritic cell subsets facilitates CD4⁺ and CD8⁺ T cell activation to localized viral infection. Immunity 43:3554–65
    [Google Scholar]
67. Horn LA, Chariou PL, Gameiro SR, Qin H, Iida M et al. 2022. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication. J. Clin. Investig. 132:8e155148
    [Google Scholar]
68. Huang SC-C, Smith AM, Everts B, Colonna M, Pearce EL et al. 2016. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 45:4817–30
    [Google Scholar]
69. Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. 2020. CCL5 mediates CD40-driven CD4⁺ T cell tumor infiltration and immunity. JCI Insight 5:10e137263
    [Google Scholar]
70. Hui E, Cheung J, Zhu J, Su X, Taylor MJ et al. 2017. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science 355:63321428–33
    [Google Scholar]
71. Iborra S, Martínez-López M, Khouili SC, Enamorado M, Cueto FJ et al. 2016. Optimal generation of tissue-resident but not circulating memory T cells during viral infection requires crosspriming by DNGR-1⁺ dendritic cells. Immunity 45:4847–60
    [Google Scholar]
72. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS et al. 2018. Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br. J. Cancer 118:2153–61
    [Google Scholar]
73. Jacquelot N, Tellier J, Nutt SL, Belz GT. 2021. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. OncoImmunology 10:11900508
    [Google Scholar]
74. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV et al. 2014. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371:262488–98
    [Google Scholar]
75. Joshi NS, Akama-Garren EH, Lu Y, Lee D-Y, Chang GP et al. 2015. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43:3579–90
    [Google Scholar]
76. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R et al. 2017. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355:63321423–27
    [Google Scholar]
77. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 438:7069820–27
    [Google Scholar]
78. Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D et al. 2020. Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell 182:4872–85.e19
    [Google Scholar]
79. Keerthivasan S, Şenbabaoğlu Y, Martinez-Martin N, Husain B, Verschueren E et al. 2021. Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1. Immunity 54:71511–26.e8
    [Google Scholar]
80. Kenkel JA, Tseng WW, Davidson MG, Tolentino LL, Choi O et al. 2017. An immunosuppressive dendritic cell subset accumulates at secondary sites and promotes metastasis in pancreatic cancer. Cancer Res 77:154158–70
    [Google Scholar]
81. Klichinsky M, Ruella M, Shestova O, Lu XM, Best A et al. 2020. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38:8947–53
    [Google Scholar]
82. Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F et al. 2016. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res 76:5999–1008
    [Google Scholar]
83. Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB et al. 2022. LRRC15⁺ myofibroblasts dictate the stromal setpoint to suppress tumor immunity. Nature 611:148–54
    [Google Scholar]
84. Laoui D, Keirsse J, Morias Y, Van Overmeire E, Geeraerts X et al. 2016. The tumor microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumor immunity. Nat. Commun. 7:13720
    [Google Scholar]
85. Lavin Y, Merad M. 2013. Macrophages: gatekeepers of tissue integrity. Cancer Immunol Res 1:4201–9
    [Google Scholar]
86. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H et al. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159:61312–26
    [Google Scholar]
87. Leader AM, Grout JA, Maier BB, Nabet BY, Park MD et al. 2021. Single-cell analysis of human nonsmall cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39:121594–609.e12
    [Google Scholar]
88. Lemke G, Rothlin CV. 2008. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8:5327–36
    [Google Scholar]
89. Li H, Liu Z, Liu L, Zhang H, Han C et al. 2022b. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1⁺ CD8 T cells. Cell Rep. Med. 3:3100554
    [Google Scholar]
90. Li J, Byrne KT, Yan F, Yamazoe T, Chen Z et al. 2018. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49:1178–93.e7
    [Google Scholar]
91. Li Y-Y, Peng Z, Sun S, Guo K, Kong D et al. 2022a. ENPP1 inhibitor ZX-8177 enhances antitumor activity of conventional therapies by modulating tumor microenvironment. Cancer Res 82:12 Suppl.5486 (Abstr.)
    [Google Scholar]
92. Li Z, Cai X, Cai C-L, Wang J, Zhang W et al. 2011. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118:174509–18
    [Google Scholar]
93. Lin EY, Li J-F, Gnatovskiy L, Deng Y, Zhu L et al. 2006. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:2311238–46
    [Google Scholar]
94. Liu T-T, Kim S, Desai P, Kim D-H, Huang X et al. 2022. Ablation of cDC2 development by triple mutations within the Zeb2 enhancer. Nature 607:7917142–48
    [Google Scholar]
95. Liu X, Sato N, Shimosato Y, Wang T-W, Denda T et al. 2022. CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Sci 113:41182–94
    [Google Scholar]
96. Lohyer P-L, Hamon P, Laviron M, Meghraoui-Kheddar , Goncalves Eet al 2018. Macrophages of distinct origins contribute to tumor development in the lung. J. Exp. Med 215:102536–53
    [Google Scholar]
97. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C et al. 2019. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol 20:81083–97
    [Google Scholar]
98. Luheshi N, Hewitt S, Garcon F, Burke S, Watkins A et al. 2019. MEDI1191, a novel IL-12 mRNA therapy for intratumoral injection to promote TH1 transformation of the patient tumor microenvironment. Cancer Res 79:13 Suppl.5017 (Abstr.)
    [Google Scholar]
99. Ma R-Y, Zhang H, Li X-F, Zhang C-B, Selli C et al. 2020. Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. J. Exp. Med. 217:11e20191820
    [Google Scholar]
100. MacNabb BW, Tumuluru S, Chen X, Godfrey J, Kasal DN et al. 2022. Dendritic cells can prime antitumor CD8⁺ T cell responses through major histocompatibility complex cross-dressing. Immunity 55:6982–97.e8
     [Google Scholar]
101. Magen A, Hamon P, Fiaschi N, Troncoso L, Humblin E et al. 2022. Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade. bioRxiv . https://doi.org/10.1101/2022.06.22.497216
     [Crossref]
102. Maier B, Leader AM, Chen ST, Tung N, Chang C et al. 2020. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580:7802257–62
     [Google Scholar]
103. Markosyan N, Li J, Sun YH, Richman LP, Lin JH et al. 2019. Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2). J. Clin. Investig. 129:93594–609
     [Google Scholar]
104. Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard J-P 2013. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. J. Immunol. 191:42001–8
     [Google Scholar]
105. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N et al. 2012. High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. OncoImmunology 1:6829–39
     [Google Scholar]
106. Mattiuz R, Brousse C, Ambrosini M, Cancel J-C, Bessou G et al. 2021. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4⁺ and CD8⁺ T-cell protective responses to breast cancer. Clin. Transl. Immunol. 10:7e1305
     [Google Scholar]
107. Mattiuz R, Wohn C, Ghilas S, Ambrosini M, Alexandre YO et al. 2018. Novel Cre-expressing mouse strains permitting to selectively track and edit type 1 conventional dendritic cells facilitate disentangling their complexity in vivo. Front. Immunol. 9:2805
     [Google Scholar]
108. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A et al. 2011. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19:4512–26
     [Google Scholar]
109. McLane LM, Abdel-Hakeem MS, Wherry EJ. 2019. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37:457–95
     [Google Scholar]
110. Merad M, Sathe P, Helft J, Miller J, Mortha A. 2013. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31:563–604
     [Google Scholar]
111. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V et al. 2012. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13:9888–99
     [Google Scholar]
112. Molgora M, Esaulova E, Vermi W, Hou J, Chen Y et al. 2020. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182:4886–900.e17
     [Google Scholar]
113. Montalbán Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J et al. 2016. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages—a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J. Immunother. Cancer 4:49
     [Google Scholar]
114. Moussion C, Girard J-P. 2011. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479:7374542–46
     [Google Scholar]
115. Mulder K, Patel AA, Kong WT, Piot C, Halitzki E et al. 2021. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54:81883–900.e5
     [Google Scholar]
116. Nakayama M. 2014. Antigen presentation by MHC-dressed cells. Front. Immunol. 5:672
     [Google Scholar]
117. Nguyen YTM, Fujisawa M, Nguyen TB, Suehara Y, Sakamoto T et al. 2021. Tet2 deficiency in immune cells exacerbates tumor progression by increasing angiogenesis in a lung cancer model. Cancer Sci 112:124931–43
     [Google Scholar]
118. Niu F, Yu Y, Li Z, Ren Y, Li Z et al. 2022. Arginase: an emerging and promising therapeutic target for cancer treatment. Biomed. Pharmacother. 149:112840
     [Google Scholar]
119. O'Sullivan BJ, Thomas R 2002. CD40 ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-κB. J. Immunol. 168:115491–98
     [Google Scholar]
120. Paavola KJ, Roda JM, Lin VY, Chen P, O'Hollaren KP et al. 2021. The fibronectin-ILT3 interaction functions as a stromal checkpoint that suppresses myeloid cells. Cancer Immunol. Res. 9:111283–97
     [Google Scholar]
121. Pan W, Zhu S, Qu K, Meeth K, Cheng J et al. 2017. The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. Immunity 47:2284–97.e5
     [Google Scholar]
122. Park JE, Dutta B, Tse SW, Gupta N, Tan CF et al. 2019. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene 38:265158–73
     [Google Scholar]
123. Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH et al. 2020. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J. Thorac. Oncol. 15:71210–22
     [Google Scholar]
124. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. 2012. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21:6836–47
     [Google Scholar]
125. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L et al. 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19:101264–72
     [Google Scholar]
126. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J et al. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumor metastasis. Nature 475:7355222–25
     [Google Scholar]
127. Ravi J, Elbaz M, Wani NA, Nasser MW, Ganju RK. 2016. Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in nonsmall cell lung cancer by downregulation of EGFR pathway. Mol. Carcinog. 55:122063–76
     [Google Scholar]
128. Reiss KA, Yuan Y, Ueno NT, Johnson ML, Gill S et al. 2022. A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. J. Clin. Oncol. 40:16 Suppl.2533 (Abstr.)
     [Google Scholar]
129. Ridge JP, Di Rosa F, Matzinger P. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4⁺ T-helper and a T-killer cell. Nature 393:6684474–78
     [Google Scholar]
130. Rios-Doria J, Favata M, Lasky K, Feldman P, Lo Y et al. 2020. A potent and selective dual inhibitor of AXL and MERTK possesses both immunomodulatory and tumor-targeted activity. Front. Oncol. 10:598477
     [Google Scholar]
131. Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE et al. 2016. Critical role for CD103⁺/CD141⁺ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30:2324–36
     [Google Scholar]
132. Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V et al. 2020. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell 182:51252–70.e34
     [Google Scholar]
133. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M et al. 2020. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20:3174–86
     [Google Scholar]
134. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R et al. 2016. Expansion and activation of CD103⁺ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44:4924–38
     [Google Scholar]
135. Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A et al. 2016. Cancer immunotherapy with immunomodulatory anti-CD137 and anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 6:171–79
     [Google Scholar]
136. Sánchez-Paulete AR, Teijeira A, Cueto FJ, Garasa S, Pérez-Gracia JL et al. 2017. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann. Oncol. 28:xii44–55
     [Google Scholar]
137. Sangaletti S, Di Carlo E, Gariboldi S, Miotti S, Cappetti B et al. 2008. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68:219050–59
     [Google Scholar]
138. Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. 2019. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19:6307–25
     [Google Scholar]
139. Schenkel JM, Herbst RH, Canner D, Li A, Hillman M et al. 2021. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1⁺ CD8⁺ T cells in tumor-draining lymph nodes. Immunity 54:102338–53.e6
     [Google Scholar]
140. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:6684480–83
     [Google Scholar]
141. Schultze JL, Mass E, Schlitzer A. 2019. Emerging principles in myelopoiesis at homeostasis and during infection and inflammation. Immunity 50:2288–301
     [Google Scholar]
142. Severson EA, Riedlinger GM, Connelly CF, Vergilio J-A, Goldfinger M et al. 2018. Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131:222501–5
     [Google Scholar]
143. Sharma MD, Pacholczyk R, Shi H, Berrong ZJ, Zakharia Y et al. 2021. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances antitumor T cell immunity. Immunity 54:102354–71.e8
     [Google Scholar]
144. Sherman MH, Beatty GL. 2022. Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance. Annu. Rev. Pathol. 18:123–48
     [Google Scholar]
145. Sica A, Guarneri V, Gennari A. 2019. Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression. Cell Stress Chaperones 3:9284–94
     [Google Scholar]
146. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D et al. 2017. Systemic immunity is required for effective cancer immunotherapy. Cell 168:3487–502.e15
     [Google Scholar]
147. Spranger S, Bao R, Gajewski TF 2015. Melanoma-intrinsic β-catenin signaling prevents antitumor immunity. Nature 523:7559231–35
     [Google Scholar]
148. Spranger S, Dai D, Horton B, Gajewski TF. 2017. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31:5711–23.e4
     [Google Scholar]
149. Su S, Liu Q, Chen J, Chen J, Chen F et al. 2014. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell 25:5605–20
     [Google Scholar]
150. Tang K, Wu Y-H, Song Y, Yu B 2021. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J. Hematol. Oncol. 14:68
     [Google Scholar]
151. Tap WD, Singh AS, Anthony SP, Sterba M, Zhang C et al. 2022. Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT. Clin. Cancer Res. 28:2298–307
     [Google Scholar]
152. Theisen DJ, Davidson JT 4th, Briseño CG, Gargaro M, Lauron EJ et al. 2018. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science 362:6415694–99
     [Google Scholar]
153. Tirado-Gonzalez I, Descot A, Soetopo D, Nevmerzhitskaya A, Schäffer A et al. 2021. AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naïve and treatment-resistant leukemia. Cancer Discov 11:112924–43
     [Google Scholar]
154. Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H et al. 2013. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. PNAS 110:2711103–8
     [Google Scholar]
155. Tussiwand R, Lee W-L, Murphy TL, Mashayekhi M, KC W et al. 2012. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 490:7421502–7
     [Google Scholar]
156. Van den Eynde BJ, van Baren N, Baurain J-F 2020. Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma?. Annu. Rev. Cancer Biol. 4:241–56
     [Google Scholar]
157. Wakim LM, Bevan MJ. 2011. Cross-dressed dendritic cells drive memory CD8⁺ T-cell activation after viral infection. Nature 471:7340629–32
     [Google Scholar]
158. Wang F, Zhang S, Vuckovic I, Jeon R, Lerman A et al. 2018. Glycolytic stimulation is not a requirement for M2 macrophage differentiation. Cell Metab 28:3463–75.e4
     [Google Scholar]
159. Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK et al. 2022. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat. Commun. 13:3022
     [Google Scholar]
160. Willingham SB, Volkmer JP, Gentles AJ, Weissman IL. 2012. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. PNAS 109:176662–67
     [Google Scholar]
161. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ et al. 2014. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41:830–42
     [Google Scholar]
162. Wu R, Ohara RA, Jo S, Liu T-T, Ferris ST et al. 2022. Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat. Immunol. 23:1536–50
     [Google Scholar]
163. Xu MM, Pu Y, Han D, Shi Y, Cao X et al. 2017. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling. Immunity 47:2363–73.e5
     [Google Scholar]
164. Yang K, Li Y, Lian G, Lin H, Shang C et al. 2018. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Int. J. Cancer 142:112323–34
     [Google Scholar]
165. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC et al. 2012. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149:3656–70
     [Google Scholar]
166. Zelenay S, Keller AM, Whitney PG, Schraml BU, Deddouche S et al. 2012. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J. Clin. Investig. 122:51615–27
     [Google Scholar]
167. Zhang J, Huang D, Saw PE, Song E. 2022. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 43:7523–45
     [Google Scholar]
168. Zhu Y, Herndon JM, Sojka DK, Kim K-W, Knolhoff BL et al. 2017. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47:2323–38.e6
     [Google Scholar]
169. Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D et al. 2019. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity 50:51317–34.e10
     [Google Scholar]